TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2978461
Drug: Nebulization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization treatment with ipratropium bromide 30 minutes after terbutaline
Study: 21562190
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of frequency bands in classifier results
Study: 17573688
Drug: Experimental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapy
Study: 7684440
Drug: Individual risk
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual risk factors (e.g., hypothyroidism)
Study: 21765448
Drug: iptakalim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: iptakalim (5 or 10 mg/d, po) for 8 weeks
Study: 19807917
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus dalteparin (5000 IU daily subcutaneous injection for 24 weeks)
Study: 24704090
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate 0.05%
Study: 14612206
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 2 g/day (Group A)
Study: 14612206
Drug: No antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antioxidant treatment (Group D)
Study: 31194946
Drug: Low-dose extracorporeal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose extracorporeal shockwave therapy (ESWT)
Study: 31194946
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham shockwave therapy)
Study: 23421968
Drug: Fluticasone/Salmeterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/Salmeterol combination (FSC)
Study: 19347118
Drug: Intravitreal antibiotic
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal antibiotic injection, associated with topical and oral antibiotics (Group 1, n=24)
Study: 16920897
Drug: Dapoxetine (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine (AUC in young men: 2040 ng x h/mL; elderly men: 2280 ng x h/mL)
Study: 16920897
Drug: Dapoxetine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine with food (C(max) in fed state: 398 ng/mL; fasted state: 443 ng/mL)
Study: 11354238
Drug: Zotepine (50-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (50-450 mg, mean 207 +/- 125 mg/day)
Study: 30841823
Drug: BCAA (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (6 g/day) with vitamin B6 (40 mg/day)
Study: 24088189
Drug: Boswellia Serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia Serrata (BS) capsules for 6 weeks
Study: 21119150
Drug: Treatment adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adherence therapy (TAT)
Study: 8742095
Drug: Flutamide in
Normalized name: Product containing flutamide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide in combination with LHRH analogs
Study: 3882680
Drug: Fluoxetine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine twice a day (in the morning and at noon)
Study: 3882680
Drug: Fluoxetine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine once a day (in the morning)
Study: 3882680
Drug: Fluoxetine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (both regimens)
Study: 31512923
Drug: Treatment (EVGs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (EVGs or standard exercise)
Study: 25131734
Drug: Sabin IPV
Normalized name: Juniperus sabina leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabin IPV (20:32:64 DU/dose)
Study: 16199834
Drug: Ziprasidone (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80-160 mg/day)
Study: 19074536
Drug: Haloperidol (8-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (8-30 mg/day)
Study: 10510053
Drug: Abciximab (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (a platelet glycoprotein IIb/IIIa receptor antagonist)
Study: 10510053
Drug: TnT-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TnT-positive patients (TnT levels >0.1 microg/L)
Study: 10510053
Drug: TnT-negative patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TnT-negative patients (TnT levels ≤0.1 microg/L)
Study: 1827104
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg every 12 h
Study: 1827104
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK 250 mg every 6 h
Study: 7041937
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg a day)
Study: 28219190
Drug: Regular antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular antibiotic group (RAT group)
Study: 23744506
Drug: Challenge dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge dose of vaccine
Study: 15709453
Drug: TAA AQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAA AQ (triamcinolone acetonide), 220 microg, once daily for 3 weeks
Study: 15709453
Drug: FP (fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP (fluticasone propionate), 200 microg, once daily for 3 weeks
Study: 9731088
Drug: Sustained-release dexfenfluramine
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release dexfenfluramine
Study: 2978997
Drug: Isradipine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 7.5 mg three times daily
Study: 31505907
Drug: 10-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day concomitant therapy (CT)
Study: 29804294
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (ST)
Study: 31327184
Drug: 7-day clarithromycin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day clarithromycin-containing triple therapy (TT)
Study: 30672218
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (acupuncture + five-element music therapy)
Study: 30672218
Drug: Five-element music
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-element music therapy group
Study: 24835009
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment at home (10-day course)
Study: 24835009
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) at home
Study: 24835009
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment at home
Study: 22676245
Drug: TAS-108 40
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-108 40 mg/day
Study: 22676245
Drug: TAS-108 80
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-108 80 mg/day
Study: 22676245
Drug: TAS-108 120
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-108 120 mg/day
Study: 20100026
Drug: 340 mg
Normalized name: febantel 340 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 340 mg oral magnesium (170 mg twice a day) for 6.5 months
Study: 11487039
Drug: Enoxaparin in
Normalized name: enoxaparin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin in high prophylactic doses
Study: 2524387
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of ipratropium bromide
Study: 21646062
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) for ISR
Study: 7705096
Drug: CVR releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVR releasing 30 mcg of ethinyl estradiol and 650 mcg of norethindrone acetate (30/650)
Study: 7705096
Drug: CVR releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVR releasing 25 mcg of ethinyl estradiol and 650 mcg of norethindrone acetate (25/650)
Study: 3069519
Drug: Paracetamol/codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/codeine
Study: 3556264
Drug: Paracetamol/dextropropoxyphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/dextropropoxyphene
Study: 31486133
Drug: Interstitial laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interstitial laser therapy (Nd‐YAG laser) performed under sonographic control
Study: 25469720
Drug: 19-mg iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19-mg iron pills
Study: 17158426
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral cyanocobalamin (1000 microg/d) for 3 months
Study: 12914120
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg i.v. every 8 hours
Study: 12914120
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg i.v. every 8 hours
Study: 12914120
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g i.v. every 12 hours plus metronidazol 500 mg twice daily
Study: 3539737
Drug: BAY m
Normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY m 1099 (alpha-glucosidase inhibitor)
Study: 24807721
Drug: ALVAC/AIDSVax vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC/AIDSVax vaccine
Study: 24807721
Drug: C1 and
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 and V2 monoclonal antibodies isolated from RV144 vaccinees
Study: 24807721
Drug: V2 monoclonal
Normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: V2 monoclonal antibody CH58
Study: 24807721
Drug: Low IgA
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low IgA Env antibody levels
Study: 12463433
Drug: 0.2% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% glyceryl trinitrate ointment (GTN)
Study: 26908303
Drug: D‐methadone 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐methadone 40 mg PO twice daily for 12 days
Study: 26908303
Drug: D‐methadone 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐methadone 40 mg PO Q 12 hours
Study: 16120154
Drug: 2% progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% progesterone cream
Study: 6391495
Drug: Oral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gold
Study: 28033526
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC-1) with TPF ± cetuximab
Study: 23485078
Drug: Prednisone monotherapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone monotherapy (1‐2 mg/kg/d; maximal total dose, ≤60 mg)
Study: 23485078
Drug: Prednisone +
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone + fluvastatin (5 mg/d if aged <5 years; 10 mg/d if aged ≥5 years)
Study: 18800069
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg per day)
Study: 15055891
Drug: bupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 7.5 mg combined with S(+) ketamine 0.1 mg kg(‐1)
Study: 11093999
Drug: bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 10 mg
Study: 11738125
Drug: Intense Tai
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Tai Chi (48 weeks, twice per week)
Study: 7602025
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no beta-blocker therapy)
Study: 371421
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline and short-term interpersonal psychotherapy
Study: 371421
Drug: Pharmacotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy alone (tricyclic antidepressants)
Study: 29375198
Drug: Oligomeric proanthocyanidin
Normalized name: grape seed proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligomeric proanthocyanidin nutritional supplement
Study: 14711717
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (500 IU daily)
Study: 11699480
Drug: Dual acid-etched
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual acid-etched implants
Study: 11699480
Drug: Machined-surfaced implants
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machined-surfaced implants
Study: 11699480
Drug: Dual acid-etched
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual acid-etched implants in poor quality or soft bone
Study: 11699480
Drug: Machined-surfaced implants
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machined-surfaced implants in poor quality or soft bone
Study: 9441094
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of last two batches of Chinese rifapentine (750 mg to 900 mg)
Study: 2239975
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (IV IgG) 1 g/kg administered every 30 days for 6 months
Study: 2239975
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (1% albumin solution) administered every 30 days for 6 months
Study: 79080
Drug: Oral electrolyte
Normalized name: Hydralyte Oral Electrolyte Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral electrolyte solutions containing sucrose
Study: 31652479
Drug: 17‐OHPC (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17‐OHPC (250 mg IM weekly)
Study: 11347795
Drug: Methylphenidate (5
Normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5 mg bid)
Study: 3816107
Drug: Cholestyramine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 1.0 g
Study: 3816107
Drug: Colestipol hydrochloride
Normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol hydrochloride 1.3 g
Study: 19798460
Drug: Arzoxifene 20
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 20 and 40 mg
Study: 16177941
Drug: Telemonitoring with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring with outpatient treatment based on findings
Study: 30873676
Drug: Prednisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (50 mg for 5 days)
Study: 29365057
Drug: Drug Repositioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Repositioning Recommendation System (DRRS)
Study: 23128818
Drug: Remifentanil (rPCA)
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (rPCA) - 20 µg boluses using PCA pump with a lockout interval of 3 min
Study: 23128818
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (EA) - 0.125% bupivacaine with sufentanil 0.5 µg/mL in top‐up boluses every hour until delivery
Study: 22431960
Drug: Higher 3-day
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher 3-day accumulated diuretic doses after dialysis initiation
Study: 22431960
Drug: Higher time-varying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher time-varying 3-day accumulative diuretic doses
Study: 19340731
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of omeprazole
Study: 12078599
Drug: Exposed dental
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposed dental implants
Study: 2501817
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg TRH
Study: 2501817
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg TRH
Study: 843096
Drug: Commercial microsize
Normalized name: griseofulvin microsize
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial microsize griseofulvin tablets
Study: 19508323
Drug: Placebo (maltose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltose, 1 to 2 g daily for 12 weeks)
Study: 17148967
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice a day increasing to 1000 mg twice a day after 2 weeks) with rosiglitazone placebo (Met/P, N = 26)
Study: 17148967
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day) with metformin placebo (Rosi/P, N = 27)
Study: 17148967
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day) plus metformin (500 mg twice a day increasing to 1000 mg twice a day after 2 weeks; Met/Rosi, N = 25)
Study: 9100581
Drug: Canrenoate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenoate (2 x 200 mg, administered at 0800 and 1700 h before the experimental night)
Study: 8171171
Drug: Structured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured group therapy plus fluoxetine
Study: 8171171
Drug: Structured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured group therapy plus placebo
Study: 8171171
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (therapy plus fluoxetine and therapy plus placebo)
Study: 31771081
Drug: Antibiotics (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (Group I)
Study: 1576625
Drug: Loracarbef 200
Normalized name: loracarbef 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef 200 mg twice daily
Study: 17279846
Drug: Other characteristics
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other characteristics (e.g., intelligence)
Study: 16193688
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy with corticosteroids and nonsteroid antirheumatics
Study: 2167951
Drug: Single-dose dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose dactinomycin (60 micrograms/kg)
Study: 2167951
Drug: Divided-dose dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divided-dose dactinomycin (45 micrograms/kg)
Study: 2167951
Drug: Divided-dose dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divided-dose dactinomycin (15 micrograms/kg per dose times five doses)
Study: 30885591
Drug: Ribaxamase (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribaxamase (150 mg, four times per day during and for 72 hours after treatment with ceftriaxone)
Study: 2209240
Drug: Chinese traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese traditional medicine Xiao Chai Hu Tang (XCHT)
Study: 7003449
Drug: Flurbiprofen 200mg
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 200mg daily
Study: 7003449
Drug: Naproxen 750mg
Normalized name: Naproxen 750mg Oral tablet, extended release
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 750mg daily
Study: 31108488
Drug: IMPULS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPULS treatment group
Study: 28535549
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg (2 mL)
Study: 28535549
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg (1 mL)
Study: 28535549
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 mL) (Control group)
Study: 6193349
Drug: Clonidine thrice
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine thrice daily
Study: 17912223
Drug: Convective dialytic
Normalized name: Kinlytic
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Convective dialytic therapies (hemodiafiltration)
Study: 16262543
Drug: Psychological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological interventions with a weekly diary kept for 6 weeks
Study: 12011290
Drug: Oral Delta(9)-Tetrahydrocannabinol
Normalized name: delta 9-tetrahydrocannabinol acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Delta(9)-Tetrahydrocannabinol (THC)
Study: 10450481
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between treatment groups
Study: 7788007
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) treatment for a period of 2.8 (2.8) years with a mean daily dose of 77 (18) micrograms/m2
Study: 7788007
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) treatment
Study: 23427865
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 0.01 mL/min